INOVIO Announces Pricing of $17.5 Million Public Offering
Rhea-AI Summary
INOVIO (Nasdaq: INO) priced an underwritten public offering of 12,500,000 common shares with accompanying Series A and Series B warrants at a combined public offering price of $1.40 per share and warrants, expected to close on or about April 6, 2026.
The company expects gross proceeds of approximately $17.5 million before discounts, and granted the underwriter a 30-day option to purchase up to 1,875,000 additional shares and warrants. Piper Sandler is sole manager.
AI-generated analysis. Not financial advice.
Positive
- Gross proceeds of approximately $17.5 million expected
- Underwriter option provides flexibility to raise up to 1,875,000 additional shares
- Shelf registration previously declared effective on January 31, 2024 enables the offering
Negative
- Immediate dilution from issuance of 12,500,000 shares and accompanying warrants
- Potential future dilution if up to 12,500,000 warrants are exercised at $1.40
- Financing priced at $1.40 per share, which may dilute existing holders' ownership percentage
News Market Reaction – INO
On the day this news was published, INO declined 35.06%, reflecting a significant negative market reaction. Argus tracked a trough of -25.5% from its starting point during tracking. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $65M from the company's valuation, bringing the market cap to $120.22M at that time. Trading volume was exceptionally heavy at 13.1x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanners show no peers in active momentum. Mixed peer moves (e.g., NKTX +2.34%, ACTU -11.07%) point to stock-specific dynamics rather than a coordinated biotech move.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 11 | Offering priced | Negative | -7.0% | Priced $25M stock offering at $1.90 with 30-day underwriter option. |
| Nov 10 | Offering proposed | Negative | -7.0% | Announced intent to sell common stock with 30-day option for extra shares. |
| Jul 03 | Offering priced | Negative | -37.9% | Priced $25M offering of shares plus Series A and B warrants at $1.75. |
| Jul 02 | Offering proposed | Negative | -37.9% | Proposed public offering of common stock and Series A and B warrants. |
| Dec 13 | Offering priced | Negative | -38.3% | Announced $30M offering at $3.00 with warrants exercisable at $3.76. |
Past equity offerings consistently saw negative next-day moves, with an average move of about -25.59% after similar financing announcements.
Over the past year, INOVIO has repeatedly relied on public offerings of common stock and warrants for funding. Prior offerings in Dec 2024, Jul 2025, and Nov 2025 all led to notable negative price reactions, often in the mid‑ to high‑double‑digit percentage range. Today’s offering continues that financing pattern, again featuring common stock paired with Series A and Series B warrants under an existing registration framework.
Historical Comparison
In the past 12 months, INOVIO announced 5 offering-related financings. The average next-day move of -25.59% shows that equity raises have historically pressured the stock.
The company has followed a recurring pattern of public offerings combining common stock with short- and longer-dated warrants to fund ongoing development of its DNA medicine pipeline.
Market Pulse Summary
The stock dropped -35.1% in the session following this news. A negative reaction despite the added cash fits prior offering-related patterns, where similar financings produced an average move of about -25.59%. The decline reflects investor focus on dilution from new shares and warrants layered onto an already capital-dependent story. Past behavior suggests that repeated reliance on such offerings has weighed on sentiment, raising questions about how quickly the stock can stabilize after funding events.
Key Terms
underwritten public offering financial
pre-funded warrants financial
prospectus supplement regulatory
AI-generated analysis. Not financial advice.
The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by INOVIO, excluding any exercise of the underwriter's option to purchase additional securities and assuming no exercise of the accompanying Series A and Series B warrants, are expected to be approximately
Piper Sandler is acting as sole manager for the offering.
A shelf registration statement relating to the shares of common stock and accompanying Series A and Series B warrants offered in the offering described above was filed with the Securities and Exchange Commission ("SEC") on November 9, 2023 and declared effective by the SEC on January 31, 2024. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC and are available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Piper Sandler & Co., 350 North 5th Street, Suite 1000,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.
Forward-Looking Statements
This release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the public offering of INOVIO's securities, including the timing of the closing of the offering, as well as the anticipated proceeds of the offering. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in INOVIO's Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505 peter.vozzo@icrhealthcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-announces-pricing-of-17-5-million-public-offering-302732811.html
SOURCE INOVIO Pharmaceuticals, Inc.